share_log

Agape ATP | 10-Q: Q3 2024 Earnings Report

Agape ATP | 10-Q: Q3 2024 Earnings Report

Agape ATP | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/14 20:26

Moomoo AI 已提取核心信息

Agape ATP Corporation reported Q3 2024 revenue of $331,289, down 6.8% from $355,314 in Q3 2023, with complementary health therapies contributing 85.7% of total revenue. Gross profit decreased to $184,185 with a margin of 55.6%, compared to $234,728 and 66.1% in the prior year period, primarily due to lower margins in network marketing and varying health therapy services.Operating expenses increased 32.7% to $732,295, mainly driven by higher general and administrative expenses of $683,819, which included new director compensation and Nasdaq listing fees. The company's selling expenses decreased 15.6% to $41,582, while commission expenses declined to $6,894 from $14,002 year-over-year.Net loss widened to $524,039 from $324,735 in Q3 2023. As of September 30, 2024, the company maintained working capital of $2.45 million, including cash and deposits of $2.72 million. Management plans to strengthen internal controls by establishing an internal audit function and implementing comprehensive training programs by mid-2025.
Agape ATP Corporation reported Q3 2024 revenue of $331,289, down 6.8% from $355,314 in Q3 2023, with complementary health therapies contributing 85.7% of total revenue. Gross profit decreased to $184,185 with a margin of 55.6%, compared to $234,728 and 66.1% in the prior year period, primarily due to lower margins in network marketing and varying health therapy services.Operating expenses increased 32.7% to $732,295, mainly driven by higher general and administrative expenses of $683,819, which included new director compensation and Nasdaq listing fees. The company's selling expenses decreased 15.6% to $41,582, while commission expenses declined to $6,894 from $14,002 year-over-year.Net loss widened to $524,039 from $324,735 in Q3 2023. As of September 30, 2024, the company maintained working capital of $2.45 million, including cash and deposits of $2.72 million. Management plans to strengthen internal controls by establishing an internal audit function and implementing comprehensive training programs by mid-2025.
Agape ATP公司报告称2024年第三季度营业收入为331,289美元，比2023年第三季度的355,314美元下降了6.8%，综合健康疗法贡献了总营业收入的85.7%。毛利润减少至184,185美元，毛利率为55.6%，而去年同期为234,728美元和66.1%，主要由于网络营销和多样化健康疗法服务的毛利率较低。营业费用增加32.7%至732,295美元，主要是由于一般和行政费用增加至683,819美元，其中包括新的董事薪酬和纳斯达克上市费用。公司的销售费用减少15.6%至41,582美元，而佣金费用则从去年的14,002美元下降至6,894美元。净亏损扩大至524,039美元，较2023年第三季度的324,735美元有所增加。截至2024年9月30日，公司保持了245万的营运资金，包括现金和存款共272万。管理层计划通过建立内部审计职能和实施全面培训计划，在2025年中期之前加强内部控制。
Agape ATP公司报告称2024年第三季度营业收入为331,289美元，比2023年第三季度的355,314美元下降了6.8%，综合健康疗法贡献了总营业收入的85.7%。毛利润减少至184,185美元，毛利率为55.6%，而去年同期为234,728美元和66.1%，主要由于网络营销和多样化健康疗法服务的毛利率较低。营业费用增加32.7%至732,295美元，主要是由于一般和行政费用增加至683,819美元，其中包括新的董事薪酬和纳斯达克上市费用。公司的销售费用减少15.6%至41,582美元，而佣金费用则从去年的14,002美元下降至6,894美元。净亏损扩大至524,039美元，较2023年第三季度的324,735美元有所增加。截至2024年9月30日，公司保持了245万的营运资金，包括现金和存款共272万。管理层计划通过建立内部审计职能和实施全面培训计划，在2025年中期之前加强内部控制。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间